IONS·Nasdaq·US
Ionis
Ionis is a commercial-stage biotechnology company that discovers and develops RNA-targeted medicines for serious diseases, selling directly and through partners such as AstraZeneca, Biogen, GSK, Novartis, Otsuka, Roche, Sobi and PTC. It markets seven medicines, including TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI and WAYLIVRA, treating conditions such as familial chylomicronemia syndrome, hereditary angioedema, transthyretin amyloidosis, spinal muscular atrophy and ALS, and it describes itself as a pioneer in RNA-targeted medicines within the biotechnology industry.
Source: SEC 10-K Feb 26, 2026
Recent Activity
Updated Sep 24, 2026
–Pelacarsen, an experimental cholesterol drug developed by Ionis Pharmaceuticals in partnership with Novartis, failed to meet expectations in a late-stage clinical trial.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.